List of Excipients in Branded Drug VERSACLOZ

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
TruPharma LLC	VERSACLOZ	clozapine	52817-601	GLYCERIN
TruPharma LLC	VERSACLOZ	clozapine	52817-601	METHYLPARABEN SODIUM
TruPharma LLC	VERSACLOZ	clozapine	52817-601	POVIDONE

VERSACLOZ Excipient Strategy and Commercial Opportunities

Last updated: September 26, 2026

Versacloz is clozapine 50 mg/mL powder for oral suspension, developed to provide a liquid dosage form for patients who cannot reliably swallow tablets. Its commercial differentiation depends more on dosing access, handling, stability, palatability, and medication-administration workflow than on clozapine itself. The strongest opportunities are ready-to-use liquid delivery, unit-dose packaging, improved taste masking, pediatric or geriatric presentations, and differentiated pharmacy or institutional dispensing systems.

What is Versacloz and how is it formulated?

Versacloz is an orally administered clozapine product supplied as a powder that is reconstituted into an oral suspension. The labeled concentration is 50 mg/mL. Clozapine is used primarily for treatment-resistant schizophrenia and for reducing recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder under the applicable FDA labeling conditions.[1]

The product is not an aqueous solution. It is a dispersed suspension that requires controlled shaking before dosing. That distinction creates both technical risks and commercial opportunities.

Attribute	Versacloz
Active ingredient	Clozapine
Dosage form	Powder for oral suspension
Labeled concentration	50 mg/mL after reconstitution
Administration	Oral syringe or calibrated measuring device
Primary patient need	Liquid administration for patients unable to swallow tablets
Therapeutic category	Antipsychotic
Regulatory pathway	FDA-approved branded small-molecule drug
Biosimilar exposure	None; clozapine is a small molecule
Main formulation risks	Sedimentation, redispersibility, dose uniformity, palatability, microbial control, device accuracy
Main commercial barrier	Clozapine monitoring and restricted dispensing workflow

The Versacloz label identifies the formulation as a powder for suspension and provides specific reconstitution, storage, shaking, and administration instructions.[1] Any development program should treat the label's device and preparation instructions as part of the product's use system, not as secondary packaging details.

What excipients are strategically important in Versacloz?

The critical excipient functions are suspension stabilization, wetting, viscosity control, preservation, palatability, and powder flow. The exact qualitative and quantitative formula should be confirmed against the current FDA-approved labeling, regulatory filings, and supplier documentation before a formulation or freedom-to-operate decision.

Suspension stabilizers

A clozapine suspension must maintain dose uniformity after storage and permit rapid redispersion after shaking. Candidate excipient classes include:

• Microcrystalline cellulose and carboxymethylcellulose systems
• Xanthan gum
• Hydroxypropyl cellulose or hypromellose
• Colloidal silicon dioxide
• Other structured-vehicle or suspending-agent systems

The preferred platform must balance physical stability with syringeability. Excessive viscosity can impair dose withdrawal, increase residual volume in the syringe, and create administration errors.

Wetting agents

Clozapine has limited aqueous solubility. Wetting agents can improve powder dispersion and reduce floating, clumping, and adherence to the container. Sodium lauryl sulfate and related surfactant systems may support wetting, but concentration control is important because surfactants can increase bitterness, foaming, gastrointestinal tolerability concerns, and container interaction.

Preservatives and microbial control

A multidose aqueous suspension creates microbial-control requirements after reconstitution. Preservative selection must account for:

• Antimicrobial effectiveness over the labeled in-use period
• Compatibility with the suspension vehicle
• Adsorption to packaging and dosing devices
• pH stability
• Taste and mucosal tolerability
• Regulatory acceptability for chronic psychiatric treatment

A preservative-free unit-dose system could create a commercial distinction, particularly in hospitals, long-term-care facilities, and home-care settings. That strategy would shift cost into packaging and supply-chain controls.

Taste-masking excipients

Clozapine can present a significant palatability challenge. Sweeteners, flavors, bitterness suppressors, ion-exchange resins, lipid-based barriers, and polymeric taste-masking systems are potential development tools.

Taste masking must not compromise:

• Suspension redispersion
• Delivered dose
• Stability
• Syringe withdrawal
• Clozapine release
• Compatibility with enteral feeding tubes

A highly palatable formulation could expand use among adolescents, adults with swallowing impairment, patients receiving medication through feeding tubes, and patients who resist tablets because of taste, texture, or administration burden.

What formulation patents could protect a next-generation Versacloz product?

The most defensible intellectual-property strategy would focus on product-specific performance rather than broad claims to clozapine suspension technology. Potential claim categories include:

1. A clozapine suspension with defined particle-size distribution.
2. A suspension with specified sedimentation volume and redispersibility.
3. A formulation with improved taste masking at a defined clozapine concentration.
4. A preservative system that maintains microbiological quality after reconstitution.
5. A ready-to-use formulation with a defined in-use shelf life.
6. A unit-dose package that limits dose variability.
7. A formulation compatible with enteral feeding tubes.
8. A product with reduced container adhesion or reduced residual volume.
9. A device-plus-formulation combination that delivers accurate doses across the labeled range.
10. A manufacturing process that produces a reproducible suspension from a high-load clozapine powder.

Broad claims covering "clozapine in an oral suspension" would face substantial prior-art and obviousness pressure. Stronger claims would require comparative data showing a measurable advantage, such as superior redispersibility, lower dose variability, longer in-use stability, lower microbial risk, improved palatability, or better device performance.

When does Versacloz lose exclusivity?

Clozapine is an established small molecule, and the primary compound patent estate is not the principal commercial barrier for a new oral clozapine product. Market protection depends on the specific branded product, formulation patents, regulatory exclusivity, trademarks, manufacturing know-how, and the willingness of a generic sponsor to pursue an abbreviated approval route.

Versacloz does not have biosimilar exclusivity because biosimilar regulation applies to biologic products, not small-molecule clozapine. Potential competitors would generally use an ANDA, a 505(b)(2) application, or another applicable small-molecule pathway rather than a biosimilar application.[2]

Protection category	Relevance to Versacloz
Compound patent	Likely expired or commercially weak for a legacy clozapine product
Formulation patents	Potentially relevant if active, listed, and claim scope is enforceable
Method-of-use patents	Could address treatment-resistant schizophrenia, suicidality, or administration populations
Regulatory exclusivity	Must be checked in current FDA records
Orange Book listings	Must be reviewed for currently listed patents and use codes
Trademark protection	May remain relevant even after generic entry
Manufacturing know-how	Potentially important for suspension stability and dose uniformity
REMS-related exclusivity	Not a patent right and does not block generic competition

The FDA removed the requirement for prescribers, pharmacies, and patients to participate in the Clozapine Risk Evaluation and Mitigation Strategy program in 2022, although FDA-required monitoring and reporting obligations remained important to safe use.[3] The change reduced one operational barrier to generic or alternative clozapine products.

What is the Orange Book status of Versacloz?

The Orange Book should be reviewed for three separate issues:

• Whether Versacloz is listed as the reference listed drug.
• Whether any formulation or method-of-use patents are listed.
• Whether any listed patents have corresponding use codes that could be carved out in an ANDA.

An Orange Book listing does not by itself establish that a patent will block approval or survive litigation. A generic sponsor may file a Paragraph IV certification against a listed patent, submit a section viii statement for a method-of-use patent, or wait for the relevant patent term to expire.[2]

Because Orange Book entries can change, an investment or launch decision should use the current FDA electronic Orange Book record rather than historical patent summaries.

Which companies are challenging Versacloz?

A definitive challenger list requires current FDA ANDA records, Paragraph IV notices, court dockets, and company disclosures. No challenger should be treated as commercially active solely because a clozapine tablet or oral solution is available.

Potential competitors fall into four groups:

1. Generic manufacturers developing a clozapine oral suspension.
2. Compounding pharmacies providing extemporaneous clozapine liquids.
3. Manufacturers of clozapine tablets that compete for the same patients.
4. Specialty-pharmacy or institutional suppliers offering customized liquid administration.

An ANDA challenger would need to address bioequivalence, dosage-form performance, product quality, device accuracy, and any applicable patent certifications. A 505(b)(2) applicant could pursue a differentiated liquid, ready-to-use suspension, alternative concentration, or new administration device, but would face a more extensive clinical and regulatory package than a conventional generic.

What generic entry risks exist for Versacloz?

Generic entry risk is moderate to high over the long term because clozapine is an old, well-characterized active ingredient. The principal barrier is not discovery of the molecule. It is reliable manufacture of a high-concentration suspension with consistent dosing and acceptable microbial and physical stability.

Generic entry scenario	Commercial impact
Generic clozapine tablets	Substitution pressure on tablet users; limited direct substitution for liquid patients
Generic oral suspension	Direct price and formulary pressure on Versacloz
505(b)(2) ready-to-use liquid	Potential premium competitor with convenience differentiation
Compounded liquid	Localized price and access competition
Unit-dose institutional product	Stronger competition in hospitals and long-term care
Improved taste-masked product	Potentially expands the liquid market rather than only substituting for Versacloz

A generic suspension may not automatically achieve full commercial substitution if it uses a different concentration, different storage conditions, different device, or different preparation process. Pharmacies and institutions may value a product with fewer preparation steps even when the active ingredient and nominal dose are identical.

What commercial opportunities exist for Versacloz excipient innovation?

Ready-to-use suspension

A ready-to-use product would eliminate reconstitution error, reduce preparation time, and simplify home administration. The development burden would include preservative strategy, container-closure integrity, sedimentation control, in-use stability, and shipping robustness.

Unit-dose or stick-pack packaging

Unit-dose packaging could reduce cross-contamination and improve dose traceability. It is most attractive for inpatient psychiatry, long-term-care facilities, correctional healthcare, and specialty pharmacies. The disadvantages are higher packaging cost and potentially greater waste.

Improved oral syringe system

A low-residual-volume syringe with a standardized adapter could reduce dose loss and improve accuracy. Device claims may be more defensible when linked to a demonstrated dosing problem, such as withdrawal variability from a viscous suspension.

Higher-concentration formulation

A concentration above 50 mg/mL could reduce administration volume. This would be useful for patients requiring high daily doses, but it would increase the importance of dose-error controls and could complicate bioequivalence. A lower concentration could benefit pediatric or titration use but would increase volume.

Taste-masked liquid

A better-tasting formulation could improve adherence among patients with swallowing difficulty or behavioral resistance to medication. Taste testing should evaluate bitterness immediately and aftertaste several minutes after administration.

Feeding-tube compatibility

A formulation that passes through commonly used enteral tubes without clogging, adsorption, or dose loss could address an identifiable institutional need. This opportunity requires tube-material studies, flushing studies, and administration instructions.

Excipient supply and manufacturing partnerships

Specialty excipient suppliers could pursue commercial opportunities in:

• Prequalified suspending-agent blends
• Low-bioburden powder systems
• Clozapine-compatible preservative packages
• Ready-to-use vehicle concentrates
• Syringe-compatible suspension platforms
• Contract manufacturing for powder blending and filling
• Stability-indicating analytical methods

The most valuable partnership model would combine excipient formulation, device engineering, regulatory support, and commercial-scale suspension manufacturing.

How strong is the Versacloz patent estate?

The patent estate is likely stronger around formulation and delivery performance than around clozapine composition of matter. A new entrant should conduct a claim-by-claim review of U.S. patents, pending applications, Orange Book listings, foreign rights, and litigation history.

Estate component	Strategic assessment
Clozapine molecule	Low barrier because of age
General oral suspension	Vulnerable to prior art
Specific excipient ratio	Potentially protectable if performance is unexpected
Device combination	Moderate opportunity for narrow, practical claims
Taste masking	Potentially protectable with comparative data
Ready-to-use stability	Commercially valuable and potentially patentable
Manufacturing process	Important trade-secret and process-control area
Method of use	Narrower value unless tied to an approved, commercially important indication

Trade secrets may be more durable than patents for mixing order, particle engineering, filling conditions, and quality-control limits. Those trade secrets require disciplined supplier qualification, access controls, analytical fingerprinting, and manufacturing agreements.

What litigation and settlement issues affect Versacloz?

Relevant litigation questions include:

• Whether a generic sponsor has issued a Paragraph IV notice.
• Whether the product sponsor has sued within the applicable statutory period.
• Whether any settlement includes a licensed entry date.
• Whether the settlement restricts an authorized generic.
• Whether formulation or device patents are asserted separately from Orange Book patents.
• Whether a 505(b)(2) applicant faces patent litigation distinct from ANDA litigation.

No settlement date or launch date should be assumed without a filed agreement, court order, FDA record, or company disclosure. A settlement can materially change generic-entry timing even when the listed patent term appears to permit earlier entry.

What is the revenue exposure from a new clozapine liquid?

Revenue exposure depends on the size of the liquid-user population, payer substitution rules, institutional purchasing, and the availability of compounded alternatives. The direct opportunity is narrower than the total clozapine market because tablets remain the dominant dosage form.

The highest-value segments are likely:

• Patients with dysphagia
• Patients requiring feeding-tube administration
• Patients with severe adherence problems
• Long-term-care residents
• Inpatient psychiatric facilities
• Patients requiring flexible dose titration
• Caregivers who cannot reliably administer tablets

A differentiated product can protect price through lower administration burden, fewer preparation steps, improved dosing accuracy, or better institutional workflow. A formulation that only replicates the existing suspension without a measurable usability or stability advantage would face rapid price competition.

Key Takeaways

• Versacloz is a 50 mg/mL clozapine powder for oral suspension.
• Its core value is liquid administration, not molecular novelty.
• The key excipient problems are suspension stability, redispersion, taste, preservation, and dosing accuracy.
• Ready-to-use, unit-dose, taste-masked, and feeding-tube-compatible products offer the clearest commercial opportunities.
• Clozapine has no biosimilar pathway; competition would arise through ANDAs, 505(b)(2) products, compounded liquids, and tablet substitution.
• Patent value is more likely to reside in formulation performance, device integration, and manufacturing process claims than in the clozapine molecule.
• Current Orange Book records, FDA exclusivity data, Paragraph IV notices, and court dockets are required for a definitive launch-risk assessment.
• The strongest commercial product would reduce preparation and administration error while preserving dose uniformity and regulatory simplicity.

FAQs

Can a generic manufacturer substitute its clozapine suspension for Versacloz?

Substitution depends on FDA approval, product equivalence, state pharmacy law, payer rules, and whether the products use the same concentration and delivery system. A 505(b)(2) product may not receive the same substitution treatment as an ANDA-approved equivalent.

Are excipients in Versacloz protected by patent?

Individual excipients are generally not proprietary. Protection may attach to a specific combination, concentration range, manufacturing process, stability profile, or device combination supported by patent claims.

Is a clozapine oral solution easier to develop than a suspension?

A true solution can simplify dose uniformity, but clozapine's solubility, pH, taste, chemical stability, and preservative requirements may make a solution technically difficult. A suspension may offer better drug loading but creates redispersion and dose-variability risks.

Can Versacloz be administered through an enteral feeding tube?

Administration depends on the product labeling, tube size, formulation behavior, and validated flushing procedure. Tube compatibility should not be assumed from oral administration data.

What is the most commercially attractive next-generation clozapine liquid?

A ready-to-use, taste-masked, low-residual-volume product with validated feeding-tube compatibility and unit-dose or low-waste packaging would have the clearest differentiation potential.

References

1. U.S. Food and Drug Administration. (2023). Versacloz (clozapine) prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2022). FDA modifies Clozapine Risk Evaluation and Mitigation Strategy program.